654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM)

Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM)

Can a patient questionnaire VRAT reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone the ukmra prommise d trial

Teclisito Low intensity teclistamab in the outpatient setting for Relapsed Refractory multiple myeloma

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg m2 VS 200 mg m2 as a conditioning regimen prior to autologous stem cell transplantation

Transition to IRD maintenance after  DRD  induction significantly deepens response in transplant ineligible NDMM A prospective multicenter study

Safety and efficacy of elranatamab nirogacestat in patients with relapsed or refractory multiple myeloma Results from the Phase 1b MagnetisMM 4 study

Hyperfractionated cyclophosphamide bortezomib and dexamethasone for initial treatment of newly diagnosed multiple myeloma with renal dysfunction

Quantitative clinical pharmacology analysis to support the dose escalation of elranatamab nirogacestat in the MagnetisMM 4 study

Belantamab mafodotin belamaf ocular events are manageable and reversible with dose modifications guided by standard assessments

Clinical pharmacology strategies to support dose optimization of the recommended Phase 2 dose regimen of JNJ 5322 a BCMA×GPRC5D×CD3 trispecific antibody in Relapsed Refractory multiple myeloma

A randomized phase II study of daratumumab lenalidomide ixazomib and dexamethasone in transplant ineligible or deferred patients with newly diagnosed multiple myeloma Alliance Foundation Trial 41 AFT 41

A phase 2 trial of 89Zr DFO daratumumab for CD38 targeted imaging of multiple myeloma the iMMunoPET study

Real world outcomes of talquetamab in Relapsed Refractory multiple myeloma

Updated results of a first in human Phase Ⅰa Ⅰb study of QLS32015 GPRC5D×CD3 in patients pts with relapsed refractory multiple myeloma RRMM

Phase II trial of maintenance therapy with iberdomide after autologous hematopoietic cell transplant for patients with multiple myeloma previously treated with lenalidomide

Low dose teclistamab in newly diagnosed multiple myeloma patients

Elranatamab for relapsed refractory multiple myeloma – multi centre real world outcomes from the United Kingdom

Home administration of isatuximab subcutaneous by on body injector in Relapsed Refractory multiple myeloma in the Phase 3 iraklia study

Integrated modeling analyses for belantamab mafodotin in combination with standard of care in patients with Relapsed Refractory multiple myeloma RRMM from dreamm 6 dreamm 7 and dreamm 8

Updated efficacy and safety results of JNJ 5322 a novel next generation BCMA×GPRC5D×CD3 trispecific antibody in patients with Relapsed Refractory multiple myeloma

Life years and quality adjusted life years with belantamab mafodotin bortezomib and dexamethasone vs alternative regimens in patients with Relapsed Refractory multiple myeloma who received ≥1 prior line of therapy

Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti CD38 therapies

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma ALLG MM23 SEALAND

Hematologist based management of ocular adverse events using the VRA tool in newly diagnosed myeloma patients ineligible for ASCT who received belantamab mafodotin plus lenalidomide dexamethasone Updated results from the randomized part 2 of bela rd Study

Response adapted randomization to Q2W vs Q4W isatuximab beyond cycle 6 in relapsed multiple myeloma Results from a phase 2 Study of isa pd in lenalidomide and PI exposed patients

Isatuximab with bortezomib cyclophosphamide and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment Final analysis of a phase 2 study by the greek myeloma study group

Randomized phase II dose optimization study of inobrodib CCS1477 in combination with pomalidomide and dexamethasone in relapsed refractory multiple myeloma RRMM

Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients SABLe report of primary endpoint nordic myeloma study group 29 21

Melphalan weight based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma

Optimizing lenalidomide therapy in renal impairment Analysis of renal response in the prospective remnant study in transplant eligible newly diagnosed multiple myeloma

Phase 1b study of cyclophosphamide pomalidomide dexamethasone and daratumumab CPD DARA in relapsed refractory multiple myeloma Safety and efficacy in a heavily pretreated population

Health related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma RRMM An exploratory analysis of overall quality of life in dreamm 7